International Journal of Endocrinology · 2020 · 14 citations · 5 references
MedicineEndocrinologyOncologyEndocrine OncologyGastrointestinal OncologyGeneral SurgeryEndocrine Tumor DiagnosisEndocrine TumorsNeuroendocrine DisordersNeuroendocrine TumorsPancreatic DiseasesPancreatic DisordersEndocrine HypersecretionMedical Records ReviewPancreatic Endocrine DisordersPancreatic InsulinomaPancreatic Neuroendocrine NeoplasmsPancreatic Neuroendocrine Tumor DiagnosisPancreatic Neuroendocrine Tumor PathologyPancreatic Neuroendocrine Tumor Surgery
BACKGROUND: Functional pancreatic neuroendocrine neoplasms (PanNENs) are very rare disorders but have complex spectrum, including insulinoma, gastrinoma, glucagonoma, somatostatinoma, and VIPoma. Patients with PanNENs usually present with characteristic symptoms caused by corresponding hormone hypersecretion. It has always been challenging in dealing with such rare but complicated disorders. In this report, we analyzed the clinical characteristics of functional PanNENs in a large cohort of Chinese patients and summarized our clinical experience in diagnosis and treatment. METHODS: The retrospective analysis was performed in patients with a definite diagnosis of functional PanNENs hospitalized in Chinese PLA General Hospital between 2000 and 2020. The clinical characteristics, surgical information, and pathological findings were extracted from their medical records and were analyzed. RESULTS: Totally, 286 patients (gender: male 103 and female 183; age: 45.55 ± 15.23 years old) were diagnosed with definite functional PanNENs. The most frequent functional PanNENs were insulinoma (266/286) followed by glucagonoma (10/286), somatostatinoma (3/286), adrenocorticotropic hormone- (ACTH-) producing tumor (3/286), gastrinoma (2/286), and VIPoma (2/286). Nine patients were diagnosed with multiple endocrine neoplasia type 1 (MEN1) in which all the associated functional PanNENs were insulinomas. The duration from symptoms' onset to confirmed diagnosis was 3.67 ± 4.28 years. Two hundred and eighty patients with tumor localized in pancreatic or with limited metastasis underwent surgery. The symptoms associated with hormonal oversecretion were improved significantly after surgery. Five patients with unresectable metastases or tumor recurrence after surgery were administrated with systemic chemotherapy or other targeted therapies. With these various therapies, the symptoms were also partially relieved. According to findings in pathological and immunochemical examination, all the functional PanNENs were categorized into NEN-G1 (41.95%), NEN-G2 (54.90%), NEN-G3 (3.15%), and NEC-G3 (0%). CONCLUSION: Patients with suspected functional PanNENs should have a systematic endocrine examination at diagnosis. Multidisciplinary collaborations are essential for precise diagnosis and tumor localization. A successful surgery or other targeted therapies can improve the prognosis of patients with such rare but complex disorders.
5
Robert T. Jensen, Guillaume Cadiot, Maria Luisa Brandi et al. · Neuroendocrinology · 2012 · 613 citations · Full text
Medicine, Endocrinology, Oncology +13
Localization of Insulinoma Using 68Ga-DOTATATE PET/CT Scan
Pavel Nockel, Bruna Babic, Corina Millo et al. · The Journal of Clinical Endocrinology & Metabolism · 2016 · 116 citations · Full text
Clinical Management of Malignant Insulinoma: a single Institution’s experience over three decades
Jie Yu, Fan Ping, Huabing Zhang et al. · BMC Endocrine Disorders · 2018 · 30 citations · Full text
Medicine, Endocrinology, Oncology +15
Clinical outcomes of 20 Japanese patients with insulinoma treated with diazoxide
Yoshihiro Niitsu, Isao Minami, Hajime Izumiyama et al. · Endocrine Journal · 2018 · 24 citations · Full text